Preliminary experience with oral thrombopoietin-receptor agonists, primarily hetrombopag, in pediatric immune thrombocytopenia: a pilot single-center retrospective report. [PDF]
Zhang M, Wang Y, Liang H, Zhang L.
europepmc +1 more source
Thromboembolic adverse events associated with TPO-RA in ITP treatment: a pharmacovigilance analysis of the FDA Adverse Event Reporting System. [PDF]
Lu Z, Zeng Y, Shang G, Lu X.
europepmc +1 more source
Patient and Physician Experiences in Immune Thrombocytopenia. [PDF]
Hsu A, Fassett T, Pallagi S, Panch SR.
europepmc +1 more source
Overall Survival Benefit and Long-Term Safety of Romiplostim in Persistent Chemotherapy-Induced Thrombocytopenia. [PDF]
Song AB, Soff GA.
europepmc +1 more source
No increased risk of hepatic enzyme abnormalities with non-peptidic thrombopoietin receptor agonists in immune thrombocytopenia: A meta-analysis of randomized controlled trials. [PDF]
Shen N +9 more
europepmc +1 more source
Refractory Primary Immune Thrombocytopenia With Bleeding and Thrombosis: A Case Report. [PDF]
Vecchio V +4 more
europepmc +1 more source
Chemotherapy-induced thrombocytopenia: from "platelet counting" to ecological repair of the bone marrow. [PDF]
Liu T, Xie R, He Q, Ma J.
europepmc +1 more source
When Platelet Stimulation Becomes Marrow Stress: Rethinking Thrombopoietin Receptor Agonist Intensification in Pediatric Immune Thrombocytopenia. [PDF]
Aricò M.
europepmc +1 more source
Editorial: Immune thrombocytopenia (ITP) - diagnosis and treatment, volume II. [PDF]
González-López TJ.
europepmc +1 more source

